scholarly journals THE ROLE OF BETA-BLOCKERS IN VETIANGINAL THERAPY IN THE CORRECTION OF VIOLATIONS OF THE AMINO ACID SPECTRUM IN PATIENTS WITH UNSTABLE ANGINA WITH CONCOMITANT DIABETES MELLITUS

2021 ◽  
Vol 77 (3) ◽  
pp. 24-30
Author(s):  
Tetiana Bohdan ◽  
Viktor Lizogub ◽  
Viktoriia Sobol ◽  
Viktor Bohdan
Keyword(s):  
Diabetes Mellitus ◽  
Blood Plasma ◽  
Beta Blockers ◽  
Control Group ◽  
Isoleucine Leucine ◽  
Compensatory Response ◽  
Group I ◽  
Group Ii ◽  
Dm Type 2

The purpose of the study: to study the effect of bisoprolol and nebivolol on the spectrum of essential blood plasma AK in patients with concomitant diabetes mellitus (DM) type 2 in order to optimize drug treatment of this pathology in the future.Material and methods. The study involved 70 patients with NA with concomitant DM type 2, which was divided into two groups: group I (37 patients) as part of basic antianginal therapy received bisoprolol, group II (33 patients) received nebivolol. The control group (CG) consisted of 18 healthy individuals. All patients were tested for irreplaceable blood plasma AA by ion exchange liquid chromatography on an automatic analyzer AK T-339 produced by «Microtechna» (Czech Republic, Prague) at the Institute of Biochemistry named after OV Palladin NAMS of Ukraine. The following essential AAs were identified: arginine, valine, histidine, isoleucine, leucine, lysine, methionine, threonine, phenylalanine. Examination of patients was performed at the beginning of treatment and after 20 days. Results. It was determined that in patients with NA with concomitant DM type 2 under the influence of antianginal therapy in both groups significantly decreased the total amount of irreplaceable AA compared with control group, indicating an increase in intracellular metabolism as a compensatory response in coronary circulation. It should be noted that in patients of group II, in contrast to patients of group I, under the influence of treatment the level of histidine remained normal. The level of threonine significantly decreased compared to CG and the rate of patients in group I, the level of valine significantly increased compared to pre-treatment, the level of isoleucine significantly decreased compared with CG and with the rate of patients of group I. Importantly, ammonia levels returned to normal under the influence of basic therapy, which included nebivolol.Conclusion. The dynamics of changes in the levels of individual irreplaceable AA blood plasma, due to the mechanisms of their metabolic transformations in patients with NA with concomitant DM type 2 indicates greater effectiveness of nebivolol and the feasibility of its prescription іn complex of a basic antianginal therapy.

scholarly journals Association of aspartate and alanine transaminases with dyslipidemia in newly diagnosed and long duration of type 2 diabetes mellitus subjects.

2021 ◽  
Vol 28 (12) ◽  
pp. 1711-1717
Author(s):  
Nazish Waris ◽  
Samina Bano ◽  
Asher Fawwad ◽  
Abdul Basit
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Group Iv ◽  
Newly Diagnosed ◽  
Group Iii ◽  
Type 2 Dm ◽  
Group I ◽  
Group Ii ◽  
Dm Type 2

Objective: Association between alanine transaminase (ALT) and aspartate transaminase (AST) with newly diagnosed and known type 2 diabetes mellitus (DM) and to estimate association of liver enzymes with lipid profile in type 2 DM subjects. Study Design: Prospective Clinical study. Setting: Karachi University with Collaboration of Baqai Institute of Diabetology and Endocrinology. Period: November 2018 to May 2019. Material & Methods: Total 100 people were divided into four groups; Group I: 25 healthy controls with normal glucose tolerance, Group II: 25 newly diagnosed DM, Group III: 25 known DM type 2 with <5years duration and Group IV: 25 known DM type 2 between 5-10 years duration. Baseline data was collected on predesigned questionnaire. Blood samples for biochemical parameters were analyzed using standardized laboratory techniques. Results: Group I mean age (years) was 50.78±2.34, group II 50.56±1.96, group III 50.37±1.46 and group IV 56±1.36. In Group I, ALT and AST were significantly correlated to each other’s. In group II, ALT was significantly correlated with AST, triglycerides and HDL-C, while AST correlated with ALT and HDL-C. In group III, ALT was significantly correlated with AST, while AST correlated to ALT, triglycerides and HbA1c. However, in group IV, ALT was significantly correlated with AST, LDL-C and HDL-C, and, AST with ALT, total cholesterol, LDL-C and HDL-C. Conclusion: Elevated ALT and AST- the salient markers for disease of non-alcoholic fatty liver with deranged dyslipidemia were found in known type 2 DM as well as in newly diagnosed type 2 DM subjects.

scholarly journals Comparison of glucose lowering ability of Pioglitazone and Glimepiride in Steptozotocin induced type 2 diabetes mellitus male mice model

2021 ◽  
Vol 15 (6) ◽  
pp. 2156-2158
Author(s):  
Hina Aslam ◽  
Saima Rafique ◽  
Sidra Mumal ◽  
Furqan Ali Shah ◽  
Abeerah Zainub ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Control Group ◽  
Male Mice ◽  
Mice Model ◽  
Group I ◽  
Group Ii ◽  
Hba1c Levels

Introduction: Diabetes mellitus type 2 is a global health problem expanding at an alarming rate and putting individuals at high risk of microvascular and macrovascular complications. Life style modification and drugs intervention can help achieve normal glucose levels. Aim &Objective: To compare the hypoglycemic activity of glimepiride and pioglitazone in a type 2 diabetes mellitus induced male mice model. Place & Duration of study: This study was carried out in the animal house of National Institute of Health (NIH), Islamabad from 7th November 2013 till 21st January 2014. Materials & Methods: Forty albino Balb/C male mice were divided randomly into groups I-IV (n=10). Group I served as normal control group. In rest of mice from group II-IV, type 2 diabetes mellitus was induced by administration of high fat diet (HFD) for two weeks followed by low dose (40 mg/kg) intra-peritoneal streptozotocin (STZ) injections for four consecutive days. Group II served as the disease control group. Group III received Glimepiride in a dose of 2mg/kg body wt. while group IV was administered Pioglitazone in a dose of 30mg/kg body wt. Both the drugs were given orally once a day. Samples were taken at the end of ten weeks. Results: The blood samples estimated for fasting blood glucose (FBG) & glycosylated hemoglobin (HbA1c %) levels showed that both glimepiride and pioglitazone equally lowered the FBG and HbA1c% levels. However, pioglitazone lowered the FBG and HbA1c levels slightly more than Glimepride. Conclusion: Glimepiride and pioglitazone lowered the FBG and HbA1c levels in type 2 diabetes induced male mice with the later having slightly more reduction than Glimepride. Key words: Glimepiride, Pioglitazone, Streptozotocin, type 2 Diabetes Mellitus.

scholarly journals Asymptomatic Hyperuricemia and Functional State of the Kidneys in Patients with Essential Arterial Hypertension and Concomitant Diabetes Mellitus Type 2

2021 ◽  
Vol 2 (3) ◽  
pp. 100-104
Author(s):  
A. O. Ikwuka ◽  
N. G. Virstyuk
Keyword(s):  
Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Diabetes Mellitus Type 2 ◽  
Inflammatory Process ◽  
Diabetes Mellitus Type ◽  
Control Group ◽  
Group I ◽  
Essential Arterial Hypertension ◽  
Group Ii

Introduction: The manuscript analyzes the frequency of asymptomatic hyperuricemia in association with disturbance of glucose and lipid metabolism, inflammatory process, and kidney changes in patients with essential arterial hypertension (EAH) and concomitant diabetes mellitus type 2 (DM2). Aim: To determine the frequency of asymptomatic hyperuricemia in patients with EAH and concomitant DM2 and their effects on the main indicators of comorbid pathology. Materials and methods: 120 patients (51 males and 69 females), aged 45-69 years with average age being (58.2±5.7) years, were studied: 25 patients with treatment-compensated EAH, 1-2 degree, II stage (Group I); 25 patients with subcompensated DM2 (Group II) and 70 patients with treatment-compensated EAH, 1-2 degree, II stage and concomitant subcompensated DM2 (Group III). Control group consisted of 20 practically healthy volunteers - 8 (40.0%) males and 12 (60.0%) females, aged (54.7±4.9) years. Groups were randomized according to age, sex, BMI, duration of EAH and DM2. Results and discussion: Asymptomatic hyperuricemia were observed in 36.0% of group І patients, in 24.0% of group II patients and in 46.7% of group ІІІ patients. Relevant correlations were found between uric acid level in the blood and such indicators as/for systolic blood pressure (SBP), glycated hemoglobin (HbA1C), dyslipidemia, inflammatory process, and kidney damage. Conclusion: Asymptomatic hyperuricemia has a negative effect on the main indicators of comorbid pathology - in this case, EAH and concomitant DM2.

scholarly journals Study of the Osteoporotic Changes in Postmenopausal Women with Type-2 Diabetes Mellitus

2017 ◽  
Vol 18 (1) ◽  
pp. 21-26
Author(s):  
Ayesha Jahan ◽  
Rokeya Begum ◽  
Khaled Bin Shamsuddin
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Femoral Neck ◽  
Postmenopausal Women ◽  
Mineral Density ◽  
Group I ◽  
Group Ii

Introduction: Osteoporosis and Diabetes Mellitus (DM) are common medical conditions in the society with an increasing prevalence in elderly people. Osteoporosis is more common in female than male and postmenopausal women are vulnerable to it.   Objective: The aim of this study was to verify the effect of type-2 diabetes mellitus on bone mineral density in postmenopausal women and, thereby, to evaluate the risk of osteoporosis in them.   Materials and Methods: This cross-sectional study was carried out at National institute of Nuclear Medicine and Allied Sciences (NINMAS), BSMMU campus, Shahbagh, Dhaka, over a period of one year. 175 postmenopausal women were enrolled as study subjects, among them 72 (41.10%) were diabetic and rest 103 (59.90%) were nondiabetic and they were assigned as Group-I and Group-II respectively. The bone mineral density (BMD) was measured by central DEXA device at lumbar spines and left femoral neck of each study subject.   Results: The mean (±SD) ages of group-I and group-II were 58.79 (±8.06) and 58.27 (±8.39) respectively with an age range of 45 to 75 years in both cases. A total of 30 (41.66%) patients in diabetic group (group-I) and 40 (38.83%) patients in non-diabetic (group-II) had osteoporosis at lumbar spines. On the other hand, 40 (56.94%) patients in group-I and 58 (56.31%) patients in group-II had osteoporosis at femoral neck. The Odds Ratios of osteoporosis for lumbar spines and femoral. neck were 1.125 and 1.026 respectively. The differences of frequencies of osteoporosis between group-I and group-II were not statistically significant at any anatomical site and the association between osteoporosis and type-2 diabetes mellitus was not significant. According to Odds Ratio type-2 diabetes mellitus was not a risk factor for developing osteoporosis in postmenopausal women.   Conclusion: Postmenopausal women are prone to develop osteoporosis and type-2 diabetes mellitus may have adverse influence on osteoporosis, which was supported by few previous studies. This study could not establish any significant effect of type-2 diabetes mellitus on osteoporosis in postmenopausal women.Bangladesh J. Nuclear Med. 18(1): 21-26, January 2015

scholarly journals Renoprotective opportunities of Lespedeza capitata in patients with chronic kidney disease and type 2 diabetes mellitus

KIDNEYS ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 162-168
Author(s):  
S.V. Kushnirenko ◽  
D.D. Ivanov ◽  
S.A. Rotova ◽  
О.V. Kushnirenko
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Antihypertensive Therapy ◽  
Glucose Lowering ◽  
Type 2 Dm ◽  
Group I ◽  
Ckd Stage ◽  
Lespedeza Capitata ◽  
Group Ii

Background. Today, issues of renoprotection have gone beyond the use of antihypertensive therapy alone. Stable glucose-lowering and urate-lowering therapy are integral parts of modern renoprotection, which improve the functional state of the kidneys by increasing the glomerular filtration rate (GFR) and reducing the albumin excretion rate (AER) and the albumin-to-creatinine ratio (ACR). Nevertheless, hypoazotemic therapy aimed at reducing the content of nitrogenous wastes remains the leading component of the treatment of patients with chronic kidney disease (CKD). The aim of the study is the assessment of the renoprotective potential of the drug Libera (Lespedeza capitata) in patients with CKD stages 2–3 on the background of type 2 diabetes mellitus (DM). Materials and methods. The study included 107 patients with type 2 DM, aged 19 to 75 years (female — 41.1 %, male — 58.9 %), CKD stages 2–3, micro- and macroalbuminuria (category A2 and A3). The patients were divided into two groups: group I — traditional stable glucose-lowering and antihypertensive therapy (n = 50) and group II — traditional stable glucose-lowering and antihypertensive therapy in combination with Libera (Lespedeza capitata) (n = 57), which was prescribed 1 capsule t.i.d. regardless of food intake for 3 months. The criteria for the effectiveness of treatment were dynamics of GFR, AER/ACR in daily urine. The observation period for the patients was 3 months. Results. The renoprotective potential of Lespedeza capitata (Libera) was demonstrated after 3 months of treatment in the form of a significant increase in GFR in patients with CKD stage 2 in group II up to 79.0 ± 1.4 ml/min/1.73 m2 in comparison with the initial data (p < 0.01) and the results obtained in group I after 3 months of using only traditional stable glucose-lowering and antihypertensive therapy (p < 0.05). The use of Libera in the complex treatment of patients of the II group with CKD stage 3 against the background of type 2 DM for 3 months had a positive effect on nitrogen and water excretory kidney function, which manifested itself in an improvement in GFR to 56.6 ± 2.1 ml/min/1.73 m2 in comparison with the initial data (p < 0.05) and the results obtained in group I — 50.8 ± 1.9 ml/min/1.73 m2 (p < 0.05). In group I with traditional stable glucose-lowering and antihypertensive therapy, only 3 patients (9.1 %) transferred from category A2 to category A1 (normoalbuminuria) after 3 months and 2 patients (11.8 %) from category A3 to category A2. In group II, the appointment of Lespedeza capitata (Libera) in combination with stable glucose-lowering and antihypertensive therapy facilitated the transfer of 10 patients (27.8 %) from category A2 to A1 and 7 patients (33.3 %) from category A3 to A2 (p < 0.001). Conclusions. Lespedeza capitata (Libera) in combination with traditional stable glucose-lowering and antihypertensive therapy contributes to the preservation and improvement of the filtration function of the kidneys, a decrease in AER/ACR in patients with CKD stage 2–3 (3a і 3b) against the background of type 2 DM and proves renoprotective efficiency and safety.

scholarly journals Autoantibody as markers of the heart state in patients with vibration disease burdened diabetes mellitus

2020 ◽  
Vol 22 (2) ◽  
pp. 311-318
Author(s):  
L. B. Masnavieva ◽  
I. V. Kudaeva ◽  
Yu. A. Kuznetsova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Thrombus Formation ◽  
The State ◽  
Myocardial Cells ◽  
Diabetes Group ◽  
Vibration Disease ◽  
Group I ◽  
Group Ii

Physical and chemical factors, obesity, lipid metabolism disorder, diabetes affect the state of the vascular endothelium, the processes of thrombus formation, fibrinolysis and increase the risk of developing cardiovascular diseases. It can be assumed that the development and course of pathological processes in the cardiovascular system, caused by vibration disease with the onset of diabetes, will undergo changes. The purpose of the study was to assess the state of heart condition according to the level of specific autoantibodies with the combined effect of vibration disease and type 2 diabetes mellitus. Patients with vibration disease (group I), patients with type 2 diabetes (group II) and persons with vibration disease in combination with type 2 diabetes (group III) were examined. Individuals do not have a history of coronary heart disease, stroke, and myocardial infarction have been included in obsledrovanie. Serum levels of specific autoantibodies characterizing the state of the heart have been studied. It was revealed that the content of autoantibodies to 1-adrenoreceptors in patients of group I was higher than in individuals of group II. The relative content of autoantibodies to the components of the membrane and cytoplasm of myocardial cells in patients of groups I-III did not differ. It was found that elevated levels of autoantibodies to components of the membrane and cytoplasm of myocardial cells, cardiomyosin, 1-adrenoreceptors were observed more often in patients with vibration disease combined with diabetes and in persons with vibration disease than in people with diabetes. Persons with a reduced content of autoantibodies to 1-adrenergic receptors were not detected among patients of groups I and III. Changes in the levels of specific autoantibodies in persons with vibration disease may indicate the development of functional metabolic and structural changes in the heart, disorders of its electrical activity that have not yet been manifested in the form of a pathological process. Lower levels of 1-adrenoceptor autoantibodies in patients with type 2 diabetes without vibration disease can be caused by increased levels of catecholamines, which is characteristic of diabetics. Further research, including clinical data and indicators of functional diagnostics is necessary to confirm our assumptions.

scholarly journals Parameters of cardiac hemodynamics in patients with diabetes mellitus with impairment of renal function

HYPERTENSION ◽  
2021 ◽  
Vol 14 (4) ◽  
pp. 5-10
Author(s):  
I.I. Topchiy ◽  
O.N. Kirienko ◽  
P.S. Semyonovykh ◽  
D.O. Kirienko ◽  
O.I. Tsygankov ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Function ◽  
Structural Parameters ◽  
Left Ventricular ◽  
Control Group ◽  
Group I ◽  
Patients With Diabetes

Currently, diabetes mellitus (DM) is a complex global problem, which is increasing every year. So, in 2019, diabetes mellitus was detected in 463 million adults (from 20 to 79 years old) in the world. And the main cause of death in patients with diabetes mellitus is cardiovascular complications. The study was aimed investigate the features of functional and structural changes in the heart in patients with type 2 diabetes mellitus and nephropathy. A total of 98 patients with type 2 diabetes mellitus were examined, out of which 78 patients had diabetic nephropathy (DN) of varying severity. The control group consisted of 20 healthy patients. After a clinical examination, depending on the state of renal function, all patients were divided into the following groups: group I — patients with type 2 diabetes mellitus without signs of nephropathy (n = 36), group II — patients with type 2 diabetes mellitus with normal glomerular filtration rate (GFR) and albuminuria (n = 33), group III — patients with type 2 diabetes mellitus with decreased GFR and albuminuria (n = 29). To study changes in hemodynamics and structural parameters of the heart, patients underwent transthoracic echocardiography on an ULTIMA PA ultrasound machine (Radmir, Ukraine) using a sectoral phased transducer with a frequency range of 2–3 MHz according to the standard technique based on the recommendations of the American Echocardiographic Society. To determine indexing indicators, the patients underwent anthropometric measurements. Patients with DN and albuminuria and decreased GFR showed an increase in the linear dimensions of the heart in comparison with controls and patients without signs of nephropathy. With DN, patients have a significant increase in left ventricular mass and a significant increase in the detection rate of left ventricular hypertrophy up to 91.3 % in patients with albuminuria and preserved renal function and up to 100 % with a decrease in GFR.

scholarly journals FIBRINOLYTIC AND PROTEOLYTIC ACTIVITY OF BLOOD PLASMA IN PEPTIC ULCER OF THE STOMACH, TAKING INTO ACCOUNT THE PATHOGENIC STRAINS OF HELICOBACTER PYLORI

2020 ◽  
Vol 8 (1) ◽  
pp. 1-7
Author(s):  
L. M. Honcharuk ◽  
O. I. Fediv ◽  
V. T. Kulachek ◽  
Y. M. Teleki
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Blood Plasma ◽  
Proteolytic Activity ◽  
Fibrinolytic Activity ◽  
Control Group ◽  
Group Iii ◽  
Group I ◽  
Group Ii ◽  
Cag A

The purpose of the study is to investigate changes in fibrinolytic and proteolytic activity of blood plasma in patients with peptic ulcer (PU) taking into account pathogenic Helicobacter pylori (Hp) strains. Materials and methods. 93 patients with PU were examined, of which 30 patients with PU and concomitant Hp cag cag A+/vac A+ (group I), 31 patients with PU and concomitant Hp cag A-/vac A- (group II), 32 patients with PU without concomitant HP infection (group III). The control group consisted of 30 healthy individuals. Fibrinolytic activity of blood plasma was investigated with the help of lysis of azofibrin (fibrin associated with the azo dye orange), which in the alkaline medium turns a bright red color. The level of total (ТFA), enzymatic (FFA) and non-enzymatic fibrinolytic activity (NFA) was evaluated. Proteolytic activity of blood plasma was determined by the lysis of azoalbumin, azocasein and azokol. Research results. The study of fibrinolytic activity of blood plasma showed that the total fibrinolytic activity of blood plasma (TFA) in all groups was significantly higher compared to the control indicators: in patients of group I by 61.5 %, in patients by 40.9 %, in patients of group III by 30.3 %, with a significant intergroup difference between the groups. The growth of TFA was mainly due to FFA. In patients of group I, FFA increased by 2.06 times (p < 0.05), and in patients of group II – by 1.79 times (p < 0.05), in patients of group IIІ – by 1.52 times (p < 0.05) compared with the control. In patients with group I, FFA increased by 12.5 % ​​(p < 0.05) compared with group II. In all patients examined, there was an increase in the proteolytic activity of blood plasma, in particular in group I, the lysis of azoalbumin, azocasein and azocolol increased significantly 2.94 times, 2.83 times and 1.90 times, respectively, and in the patients of group II the investigated indicators increased accordingly 1.87-fold (p < 0.05), 1.96-fold (p < 0.05) and 1.40-fold (p < 0.05), in patients of group III, respectively 1.55 times (p < 0.05), 1.59 times (p < 0.05) and 1.18 times, compared to these values ​​in almost healthy subjects. Significantly more significant changes in proteolysis were detected in the presence of pathogenic Hp strains. Conclusion. Increased proteolytic and fibrinolytic activity of blood plasma is observed in patients with PU. The presence of concomitant Hp in PU leads to more pronounced changes in proteolysis and fibrinolysis. Pathogenic strains of Hp cag cag A+/vac A+ cause significantly more abnormalities in hemostasis.

scholarly journals A COMPARATIVE STUDY OF EFFICACY AND SAFETY AMONG METFORMIN WITH SITAGLIPTIN, METFORMIN WITH VOGLIBOSE, AND METFORMIN WITH GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

2017 ◽  
Vol 10 (12) ◽  
pp. 313
Author(s):  
Kala P ◽  
Jamuna Rani R ◽  
Kumar Js
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Glucose ◽  
P Value ◽  
Efficacy And Safety ◽  
Group Iii ◽  
Group I ◽  
Group Ii

Objective: Type 2 diabetes mellitus (DM) is a most common metabolic disorder. The present study aimed to compare the efficacy and safety among metformin with sitagliptin, metformin with voglibose, and metformin with glimepiride in patients with type 2 DM. Methods: This study was a prospective, randomized clinical trial study, conducted in patients attending the diabetology outpatient department of SRM Medical College Hospital and Research Center, Potheri, Kancheepuram, Tamil Nadu, from January 2013 to January 2014. The patients were randomized into three groups with 40 patients in each group. Fasting plasma glucose (FPG), 2 hrs postprandial plasma glucose (PPG), and hemoglobin A1c (HbA1c) level were assessed in all the patients before starting the treatment. In Group I, patients were prescribed metformin 500 mg with sitagliptin 50 mg, in Group II, patients were given metformin 500 mg with voglibose 0.2 mg, and in Group III, patients were put on metformin 500 mg with glimepiride 1 mg in the fixed combination. The outcome of the therapy was based on the level of improvement in the blood parameters. Results: There was a significant reduction of FPG level seen in all three groups (p value - Group I <0.0001, Group II < 0.005, and Group III <0.0001). Group I and III showed significant reduction of PPG with p value <0.0001. There was a significant reduction of HbA1c seen in all the three groups (p<0.0001). Conclusion: From the results of this study, it could be concluded that all the three groups were comparable in their efficacy.

scholarly journals Indicators of microcirculation in patients with type 2 diabetes with diabetic peripheral neuropathy during therapy with various doses of vitamin D

2019 ◽  
Vol 18 (4) ◽  
pp. 19-28
Author(s):  
A. P. Stepanova ◽  
T. L. Karonova ◽  
M. M. Galagoudza
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Functional Tests ◽  
Disability Score ◽  
Doppler Flowmetry ◽  
Group I ◽  
Group Ii

Aim of the study. To study the effect of therapy with prophylactic and supraphysiological doses of cholecalciferol on skin microcirculation (MC) indicators in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy (T2DM with DPN).Material and methods. The study included 62 participants with T2DM with DPN (according to the Neuropathy Disability Score (NDS) scale, more than 4 points). By the method of consecutive numbers, patients were randomized into two groups: Group I (n=31, 15 men/16 women, 52.4±5.7 years) and Group II (n=31, 16 men/15 women, 51.4±6.1 years). Antihyperglycemic treatment was stable during the study. For 24 weeks, cholecalciferol participants from Group I received once a week at a dose of 5,000 IU, and from Group II - once a week at a dose of 40,000 IU. Body mass index (BMI), serum levels of 25(OH)D (25-hydroxycalciferol) and serum glycated hemoglobin (HbA1c) were evaluated before and after 24 weeks of taking cholecalciferol. The method of laser Doppler flowmetry (LDF) compared the initial and final indicators of the baseline level of blood flow and microcirculation indicators against the background of functional tests (postural and occlusive). Control measurements of LDF parameters were performed on 16 subjects without revealed diabetes mellitus (8 men/8 women, 51.8±3.7 years).Results. Patients from Group II, after 24 weeks of taking supraphysiological doses of cholecalciferol, against the background of 100% normalization of the serum 25(OH)D level, significantly improved the parameters of skin MC and functional tests, HbA1c and BMI decreased.Conclusions. Acceptance of high doses of cholecalciferol for 24 weeks has been associated with an improvement in the parameters of glycaemia and indicators of cutaneous MC in patients with T2DM with DPN.

Sign in / Sign up

Export Citation Format

Share Document